← All posts

Best Weight-loss Drug (Semaglutide, Tirzepatide, and Retatrutide)

Written by Beth from the Radiance Peptides Research Team · May 21, 2026

Research question

“Semaglutide, Tirzepatide, and Retatrutide: create a clinical comparison”

Key Takeaways

Clinical trials demonstrate a clear efficacy progression across three generations of incretin-based therapies: semaglutide achieves approximately 15% weight loss, tirzepatide reaches 21% through dual GLP-1/GIP receptor activation, and retatrutide produces the highest weight loss at 24.2% via triple receptor targeting (GLP-1/GIP/glucagon). All three agents provide substantial glycemic control with HbA1c reductions of 1.3-2.0%, but differ significantly in cardiovascular evidence maturity and regulatory approval status.

Semaglutide provides established cardiovascular protection and achieved 28.7 percentage-point improvement over placebo in liver disease resolution in Phase 3 trials.
Tirzepatide's dual receptor mechanism produced superior weight loss with 57% of participants achieving ≥20% weight reduction at the 15mg dose versus 3% with placebo.
Retatrutide demonstrated the highest efficacy with 100% of participants achieving ≥5% weight loss and 83% achieving ≥15% weight loss at the 12mg dose.
Glycemic control improves across all three agents, with 95% of prediabetic patients returning to normoglycemia on tirzepatide and 82% reaching HbA1c ≤6.5% on retatrutide.
Gastrointestinal adverse events remain consistent across all three drugs, with nausea risk 2.59 times higher than placebo for semaglutide and similar profiles for the others.
Regulatory approval status varies significantly: semaglutide and tirzepatide are FDA-approved for both diabetes and weight management, while retatrutide remains investigational in Phase 3 trials.

Mechanism of Action

Incretin-based pharmacology has advanced rapidly through three successive receptor-targeting strategies, each building on the limitations of its predecessor.

Semaglutide is a selective GLP-1 receptor agonist. Its mechanism recapitulates native GLP-1 signaling: it stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and engages central appetite-regulating circuits across the hypothalamus and brainstem. Its metabolic footprint extends across the pancreas, gastrointestinal tract, adipose tissue, and central nervous system.

Tirzepatide is engineered as a single molecule that co-activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Its receptor affinity profile is worth noting precisely: tirzepatide binds the GLP-1 receptor at approximately 20% of the affinity of native GLP-1, compared to semaglutide's 60%, while its potency and affinity at the GIP receptor closely match those of endogenous human GIP. The practical implication is that tirzepatide is not simply a more potent GLP-1 agonist — it is a pharmacologically distinct entity in which GIP receptor engagement carries independent metabolic weight. That engagement is hypothesized to expand the buffering capacity of white adipose tissue and attenuate myocardial lipotoxicity through mechanisms beyond those attributable to weight reduction alone.

Retatrutide (LY3437943) adds a third axis: glucagon receptor (GCG) co-activation. It is a 39-amino acid peptide built on a GIP backbone, conjugated to a C20 fatty diacid moiety that enables albumin binding and extends its half-life to approximately six days, supporting once-weekly subcutaneous administration. Its receptor potency profile is precisely characterized: approximately 2.5-fold lower potency at the GLP-1 receptor than native GLP-1, 8.9-fold higher potency at the GIP receptor than native GIP, and 2.9-fold lower potency at the glucagon receptor than endogenous GCG. The addition of glucagon receptor activation introduces a mechanism not present in either semaglutide or tirzepatide — a clinically meaningful increase in energy expenditure driven by enhanced hepatic glucose output and thermogenic signaling. Retatrutide has completed Phase 2 trials for obesity and type 2 diabetes (T2DM), with Phase 3 studies currently ongoing.

Weight Loss Efficacy

The generational progression across these three compounds is most clearly quantified in weight reduction outcomes.

Semaglutide at 2.4 mg weekly (Wegovy®) achieves approximately 15% reduction in initial body weight in adults with obesity without T2DM at 68 weeks. In non-diabetic populations, this corresponds to reductions in waist circumference of 9.39 cm, BMI of 4.27 kg/m², and systolic blood pressure of 4.78 mmHg. Weight loss is consistently attenuated in patients with T2DM — a pattern replicated across the incretin class. A meta-analysis of 33 randomized controlled trials found that 33.4% of all participants failed to achieve ≥5% total body weight reduction, with non-response rates substantially higher in the T2DM cohort.

Tirzepatide, across the SURMOUNT program at weekly doses from 5 mg to 15 mg, produced dose-dependent weight loss of up to 21% in non-diabetic participants and up to 15% in those with T2DM. At the 15 mg dose, 57% of participants achieved ≥20% weight loss, compared with 3% in the placebo group. A secondary finding of notable metabolic significance: at week 72, 95% of participants with prediabetes at baseline in the tirzepatide groups returned to normoglycemia.

Retatrutide's Phase 2 data represent the highest weight loss figures reported among this class at the time of this comparison. Mean weight reductions reached 22.8% at the 8 mg dose and 24.2% at the 12 mg dose at 48 weeks in individuals with obesity. The dose-response was striking: at 12 mg, 100% of participants achieved ≥5% weight loss, 93% achieved ≥10%, and 83% achieved ≥15%, versus 27%, 9%, and 2% for placebo, respectively. Participants had not reached a weight loss plateau by the end of the Phase 2 observation period, suggesting Phase 3 data at longer durations may yield even greater reductions.

Glycemic Control

Semaglutide reduces HbA1c by approximately 1.55% at the 1.0 mg dose. In one meta-analysis, fasting blood glucose fell by a mean of 5.46 mmol/L.

Tirzepatide, across the SURPASS program at 5 mg to 15 mg weekly, produces consistent HbA1c reductions in T2DM, with accompanying improvements in beta-cell function and insulin sensitivity. The dose-dependent glycemic benefit is well-characterized across the clinical trial program.

Retatrutide's T2DM Phase 2 trial demonstrated HbA1c reductions of 1.3% to 2.0% across dose levels, with 82% of participants reaching an HbA1c of ≤6.5%. Its insulinotropic effects derive from dual GIP and GLP-1 receptor activation. Critically, the glucagon receptor component — which would be expected to raise blood glucose in isolation — is counterbalanced by the incretin axes such that glucose-elevating effects are not clinically dominant in the context of dual co-agonism.

Cardiometabolic and Organ-Specific Outcomes

Semaglutide has the most mature cardiovascular evidence base. It holds regulatory approval to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease and obesity or overweight. In the Phase 3 ESSENCE trial for metabolic dysfunction-associated steatohepatitis (MASH), semaglutide 2.4 mg weekly produced a 28.7 percentage-point difference over placebo in MASH resolution without fibrosis worsening, and a 14.4 percentage-point difference over placebo in fibrosis improvement without MASH worsening — with 32.7% of semaglutide-treated patients achieving both endpoints simultaneously. In chronic kidney disease with T2DM, semaglutide reduced the rate of major kidney disease events versus placebo. No drug-induced liver injury signals were identified in the MASH population.

Tirzepatide has generated a favorable cardiovascular signal in real-world data. In a study of patients aged 40 and older with pre-existing ischemic heart disease, tirzepatide was associated with a statistically significant reduction in the composite endpoint of acute myocardial infarction, ischemic stroke, and all-cause mortality compared to GLP-1 receptor agonists alone. Secondary outcome reductions included heart failure events, new-onset systolic heart failure, atrial arrhythmias, and new acute kidney injury. Tirzepatide has also demonstrated reductions in liver fat and improved steatohepatitis endpoints in biopsy-confirmed MASH.

Retatrutide produced substantial reductions in liver fat — up to 82.4% at 24 weeks with higher doses — in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), as well as significant reductions in the urine albumin-to-creatinine ratio (UACR) compared to placebo in post-hoc analyses, suggesting a potential renal-protective effect. A body composition sub-study confirmed that weight loss under retatrutide involved meaningful fat mass reduction while preserving lean mass proportionally more effectively than placebo. Cardiovascular outcome trial data for retatrutide have not been published; this represents a significant evidence gap that Phase 3 data will need to address.

Safety and Tolerability

All three agents share a class-level adverse event profile dominated by gastrointestinal symptoms, with nausea, diarrhea, vomiting, and constipation as the predominant manifestations. The underlying mechanism — GLP-1-mediated s

References

› Sources (30)